Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin add-on to metformin and sulfonylurea in T2DM
NCT01076075Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin with Placebo / Pioglitazone (2 arms). Primary endpoints: Change From Baseline in Hemoglobin A1C at 24 weeks, Number of Participants With One or More Adverse Events at 54 weeks and 1 more. Started Jun 2010; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01076075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01076075.